Bryce Point Capital LLC Takes $601,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Bryce Point Capital LLC purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 23,790 shares of the biopharmaceutical company's stock, valued at approximately $601,000.

A number of other hedge funds have also made changes to their positions in the stock. EverSource Wealth Advisors LLC boosted its position in Celldex Therapeutics by 215.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 878 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Celldex Therapeutics in the fourth quarter worth $81,000. KBC Group NV boosted its holdings in shares of Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after buying an additional 1,647 shares during the period. AlphaQuest LLC grew its stake in Celldex Therapeutics by 171.0% in the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock valued at $108,000 after buying an additional 2,705 shares during the last quarter. Finally, E Fund Management Co. Ltd. bought a new position in Celldex Therapeutics in the 4th quarter worth $273,000.

Celldex Therapeutics Stock Up 2.3 %

CLDX traded up $0.37 during trading on Tuesday, reaching $16.10. 277,497 shares of the company's stock were exchanged, compared to its average volume of 868,051. The company has a market capitalization of $1.07 billion, a P/E ratio of -6.26 and a beta of 1.59. The business has a 50 day moving average price of $21.01 and a 200 day moving average price of $25.16. Celldex Therapeutics, Inc. has a fifty-two week low of $14.61 and a fifty-two week high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The business had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million. As a group, research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Analyst Ratings Changes

A number of research firms have issued reports on CLDX. Morgan Stanley started coverage on shares of Celldex Therapeutics in a report on Thursday, March 20th. They set an "overweight" rating and a $46.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Friday, February 28th. UBS Group assumed coverage on Celldex Therapeutics in a report on Thursday, February 13th. They set a "buy" rating and a $44.00 price target for the company. The Goldman Sachs Group lowered their price objective on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $54.33.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.